US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
DE3280400D1
(de)
|
1981-10-23 |
1992-06-04 |
Molecular Biosystems Inc |
Oligonukleotides heilmittel und dessen herstellungsverfahren.
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
JPS5927900A
(ja)
|
1982-08-09 |
1984-02-14 |
Wakunaga Seiyaku Kk |
固定化オリゴヌクレオチド
|
FR2540122B1
(fr)
|
1983-01-27 |
1985-11-29 |
Centre Nat Rech Scient |
Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
|
US4605735A
(en)
|
1983-02-14 |
1986-08-12 |
Wakunaga Seiyaku Kabushiki Kaisha |
Oligonucleotide derivatives
|
US4948882A
(en)
|
1983-02-22 |
1990-08-14 |
Syngene, Inc. |
Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
|
US4824941A
(en)
|
1983-03-10 |
1989-04-25 |
Julian Gordon |
Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
|
DE3329892A1
(de)
|
1983-08-18 |
1985-03-07 |
Köster, Hubert, Prof. Dr., 2000 Hamburg |
Verfahren zur herstellung von oligonucleotiden
|
US4587044A
(en)
|
1983-09-01 |
1986-05-06 |
The Johns Hopkins University |
Linkage of proteins to nucleic acids
|
US5118802A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
US5430136A
(en)
|
1984-10-16 |
1995-07-04 |
Chiron Corporation |
Oligonucleotides having selectably cleavable and/or abasic sites
|
US5258506A
(en)
|
1984-10-16 |
1993-11-02 |
Chiron Corporation |
Photolabile reagents for incorporation into oligonucleotide chains
|
US4828979A
(en)
|
1984-11-08 |
1989-05-09 |
Life Technologies, Inc. |
Nucleotide analogs for nucleic acid labeling and detection
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
US5405938A
(en)
|
1989-12-20 |
1995-04-11 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US4762779A
(en)
|
1985-06-13 |
1988-08-09 |
Amgen Inc. |
Compositions and methods for functionalizing nucleic acids
|
US5317098A
(en)
|
1986-03-17 |
1994-05-31 |
Hiroaki Shizuya |
Non-radioisotope tagging of fragments
|
JPS638396A
(ja)
|
1986-06-30 |
1988-01-14 |
Wakunaga Pharmaceut Co Ltd |
ポリ標識化オリゴヌクレオチド誘導体
|
DE3788914T2
(de)
|
1986-09-08 |
1994-08-25 |
Ajinomoto Kk |
Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
JP2828642B2
(ja)
|
1987-06-24 |
1998-11-25 |
ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン |
ヌクレオシド誘導体
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
WO1989005358A1
(en)
|
1987-11-30 |
1989-06-15 |
University Of Iowa Research Foundation |
Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
US5082830A
(en)
|
1988-02-26 |
1992-01-21 |
Enzo Biochem, Inc. |
End labeled nucleotide probe
|
EP0406309A4
(en)
|
1988-03-25 |
1992-08-19 |
The University Of Virginia Alumni Patents Foundation |
Oligonucleotide n-alkylphosphoramidates
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
US5109124A
(en)
|
1988-06-01 |
1992-04-28 |
Biogen, Inc. |
Nucleic acid probe linked to a label having a terminal cysteine
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
US5262536A
(en)
|
1988-09-15 |
1993-11-16 |
E. I. Du Pont De Nemours And Company |
Reagents for the preparation of 5'-tagged oligonucleotides
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
US5599923A
(en)
|
1989-03-06 |
1997-02-04 |
Board Of Regents, University Of Tx |
Texaphyrin metal complexes having improved functionalization
|
US5457183A
(en)
|
1989-03-06 |
1995-10-10 |
Board Of Regents, The University Of Texas System |
Hydroxylated texaphyrins
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
US5451463A
(en)
|
1989-08-28 |
1995-09-19 |
Clontech Laboratories, Inc. |
Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
US5254469A
(en)
|
1989-09-12 |
1993-10-19 |
Eastman Kodak Company |
Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
US5292873A
(en)
|
1989-11-29 |
1994-03-08 |
The Research Foundation Of State University Of New York |
Nucleic acids labeled with naphthoquinone probe
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US6395492B1
(en)
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
AU7579991A
(en)
|
1990-02-20 |
1991-09-18 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
EP0455905B1
(en)
|
1990-05-11 |
1998-06-17 |
Microprobe Corporation |
Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
|
DE69126530T2
(de)
|
1990-07-27 |
1998-02-05 |
Isis Pharmaceutical, Inc., Carlsbad, Calif. |
Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
PT98562B
(pt)
|
1990-08-03 |
1999-01-29 |
Sanofi Sa |
Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases
|
US5245022A
(en)
|
1990-08-03 |
1993-09-14 |
Sterling Drug, Inc. |
Exonuclease resistant terminally substituted oligonucleotides
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
EP0549686A4
(en)
|
1990-09-20 |
1995-01-18 |
Gilead Sciences Inc |
Modified internucleoside linkages
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
DE69132510T2
(de)
|
1990-11-08 |
2001-05-03 |
Hybridon, Inc. |
Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden
|
US5965722A
(en)
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
US5371241A
(en)
|
1991-07-19 |
1994-12-06 |
Pharmacia P-L Biochemicals Inc. |
Fluorescein labelled phosphoramidites
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
US6831166B2
(en)
|
1992-10-23 |
2004-12-14 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
US20060270624A1
(en)
|
1991-12-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
DE69233599T2
(de)
|
1991-12-24 |
2006-12-14 |
Isis Pharmaceuticals, Inc., Carlsbad |
Unterbrochene 2'-modifizierte Oligonukleotide
|
US5565552A
(en)
|
1992-01-21 |
1996-10-15 |
Pharmacyclics, Inc. |
Method of expanded porphyrin-oligonucleotide conjugate synthesis
|
US5595726A
(en)
|
1992-01-21 |
1997-01-21 |
Pharmacyclics, Inc. |
Chromophore probe for detection of nucleic acid
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
US5434257A
(en)
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
NL9300058A
(nl)
|
1992-06-18 |
1994-01-17 |
Stichting Rega V Z W |
1,5-anhydrohexitol nucleoside analoga en farmaceutisch gebruik daarvan.
|
US5272250A
(en)
|
1992-07-10 |
1993-12-21 |
Spielvogel Bernard F |
Boronated phosphoramidate compounds
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
TW244371B
(da)
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
ATE162198T1
(de)
|
1992-07-27 |
1998-01-15 |
Hybridon Inc |
Oligonukleotid alkylphosphonothiate
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
EP0677056B1
(en)
|
1993-01-25 |
1996-05-22 |
HYBRIDON, Inc. |
Oligonucleotide alkylphosphonates and alkylphosphonothioates
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
CA2159629A1
(en)
|
1993-03-31 |
1994-10-13 |
Sanofi |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
EP0733059B1
(en)
|
1993-12-09 |
2000-09-13 |
Thomas Jefferson University |
Compounds and methods for site-directed mutations in eukaryotic cells
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
US5597696A
(en)
|
1994-07-18 |
1997-01-28 |
Becton Dickinson And Company |
Covalent cyanine dye oligonucleotide conjugates
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
US5734039A
(en)
|
1994-09-15 |
1998-03-31 |
Thomas Jefferson University |
Antisense oligonucleotides targeting cooperating oncogenes
|
US6608035B1
(en)
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
US8217015B2
(en)
|
2003-04-04 |
2012-07-10 |
Arrowhead Madison Inc. |
Endosomolytic polymers
|
DK0882061T3
(da)
|
1996-02-14 |
2004-09-27 |
Isis Pharmaceuticals Inc |
Sukkermodificerede gapped oligonukleotider
|
WO1997030064A1
(en)
|
1996-02-16 |
1997-08-21 |
Stichting Rega Vzw |
Hexitol containing oligonucleotides and their use in antisense strategies
|
US6015710A
(en)
|
1996-04-09 |
2000-01-18 |
The University Of Texas System |
Modulation of mammalian telomerase by peptide nucleic acids
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US5912332A
(en)
|
1996-07-26 |
1999-06-15 |
Hybridon, Inc. |
Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
AU1292899A
(en)
|
1997-11-07 |
1999-05-31 |
Isis Pharmaceuticals, Inc. |
Pyrimidine derivatives for labeled binding partners
|
AU3751299A
(en)
|
1998-04-20 |
1999-11-08 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
AU4595399A
(en)
|
1998-06-19 |
2000-01-10 |
Mcgill University |
Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
|
EP0979869A1
(en)
*
|
1998-08-07 |
2000-02-16 |
Hoechst Marion Roussel Deutschland GmbH |
Short oligonucleotides for the inhibition of VEGF expression
|
US6228642B1
(en)
|
1998-10-05 |
2001-05-08 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
CZ296576B6
(cs)
|
1999-02-12 |
2006-04-12 |
Sankyo Company Limited |
Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
|
KR20000065690A
(ko)
*
|
1999-04-08 |
2000-11-15 |
박종구 |
반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 dna 및 그 제조방법
|
US20080281041A1
(en)
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
WO2001018003A1
(en)
|
1999-09-10 |
2001-03-15 |
Stichting Rega Vzw |
Carbocyclic nucleosides and process for obtaining such
|
JP2003511016A
(ja)
|
1999-10-04 |
2003-03-25 |
エクシコン エ/エス |
オリゴヌクレオチドを補充する高親和性rnアーゼhの設計
|
EP1240322A2
(en)
|
1999-12-23 |
2002-09-18 |
Exiqon A/S |
Therapeutic uses of lna-modified oligonucleotides
|
EP1244667B1
(en)
|
1999-12-30 |
2006-04-05 |
K.U. Leuven Research & Development |
Cyclohexene nucleic acids
|
US6602857B1
(en)
|
2000-01-18 |
2003-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
DE60110244T2
(de)
|
2000-09-06 |
2006-01-19 |
Mcgill University, Montreal |
Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribosenukleotide
|
CA2437942C
(en)
|
2000-11-09 |
2013-06-11 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
JP2005508634A
(ja)
|
2001-10-29 |
2005-04-07 |
マクギル・ユニヴァーシティ |
非環式リンカー含有オリゴヌクレオチド及びその用途
|
CN101044154A
(zh)
|
2002-02-14 |
2007-09-26 |
威廉·J·鲁特 |
治疗宿主中切割的嵌合分子
|
US20080207542A1
(en)
*
|
2002-03-26 |
2008-08-28 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
EP2264172B1
(en)
|
2002-04-05 |
2017-09-27 |
Roche Innovation Center Copenhagen A/S |
Oligomeric compounds for the modulation of hif-1alpha expression
|
US20030228690A1
(en)
|
2002-06-10 |
2003-12-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of IL-1 receptor-associated kinase-1 expression
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
US20050130924A1
(en)
|
2002-06-26 |
2005-06-16 |
Monia Brett P. |
Antisense inhibition via RNAse H-independent reduction in mRNA
|
WO2004044132A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
ES2607471T3
(es)
|
2002-11-18 |
2017-03-31 |
Roche Innovation Center Copenhagen A/S |
Diseño antisentido
|
WO2004069992A2
(en)
|
2003-02-10 |
2004-08-19 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of ras expression
|
FR2853663B1
(fr)
|
2003-04-14 |
2007-08-31 |
Aventis Pharma Sa |
Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
|
US20080124317A1
(en)
*
|
2003-06-25 |
2008-05-29 |
Orna Mor |
Diagnos and Treatment of Fibrosis Related Pathology
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
GB0324854D0
(en)
|
2003-10-24 |
2003-11-26 |
Expresson Biosystems Ltd |
App/ena antisense
|
KR101107818B1
(ko)
|
2003-10-30 |
2012-01-31 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
향상된 면역자극 효능을 가진 c-부류 올리고뉴클레오티드유사체
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
AU2004303464B2
(en)
*
|
2003-12-23 |
2009-10-01 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of BCL-2
|
CA2553104A1
(en)
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
EP2330111A3
(en)
*
|
2004-01-30 |
2011-08-17 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
|
US8314226B2
(en)
|
2004-03-29 |
2012-11-20 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
CN101031658A
(zh)
|
2004-05-26 |
2007-09-05 |
罗塞塔金诺米克斯有限公司 |
病毒和病毒相关mirna及其用途
|
JP2008501693A
(ja)
|
2004-06-03 |
2008-01-24 |
アイシス ファーマシューティカルズ、インク. |
遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
WO2006086667A2
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
DE102005036654A1
(de)
|
2005-08-04 |
2007-02-15 |
Bayer Materialscience Ag |
Selbstvernetzende PUR-Dispersionen mit Uretdionstruktur
|
AU2006315102A1
(en)
|
2005-11-21 |
2007-05-24 |
Johnson & Johnson Research Pty Limited |
Multitargeting interfering RNAs having two active strands and methods for their design and use
|
US20090011004A1
(en)
|
2005-12-30 |
2009-01-08 |
Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine |
Improved carriers for delivery of nucleic acid agents to cells and tissues
|
PL2314594T3
(pl)
|
2006-01-27 |
2014-12-31 |
Isis Pharmaceuticals Inc |
Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
|
EP1984499B1
(en)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
US8362229B2
(en)
*
|
2006-02-08 |
2013-01-29 |
Quark Pharmaceuticals, Inc. |
Tandem siRNAS
|
MX2008012219A
(es)
|
2006-04-03 |
2008-10-02 |
Santaris Pharma As |
Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
|
JP2009536222A
(ja)
|
2006-05-05 |
2009-10-08 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Pcsk9の発現を調節するための化合物および方法
|
JP5274461B2
(ja)
|
2006-08-18 |
2013-08-28 |
アローヘッド リサーチ コーポレイション |
ポリヌクレオチドのインビボ送達のためのポリ結合体
|
WO2008029619A1
(fr)
|
2006-09-07 |
2008-03-13 |
Daiichi Sankyo Company, Limited |
Oligonucléotide antisens ena ayant une action spécifique de la séquence
|
US20100216864A1
(en)
|
2006-10-09 |
2010-08-26 |
Ellen Marie Straarup |
RNA Antagonist Compounds for the Modulation of PCSK9
|
DK2092065T4
(da)
|
2006-10-18 |
2019-10-21 |
Ionis Pharmaceuticals Inc |
Antisense-forbindelser
|
US20080311040A1
(en)
*
|
2007-03-06 |
2008-12-18 |
Flagship Ventures |
METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
WO2009023819A2
(en)
|
2007-08-15 |
2009-02-19 |
Idera Pharmaceuticals, Inc. |
Toll like receptor modulators
|
MY156951A
(en)
|
2007-10-04 |
2016-04-15 |
Santaris Pharma As |
Micromirs
|
EP2205746A4
(en)
|
2007-10-04 |
2010-12-22 |
Univ Texas |
MODULATION OF GENE EXPRESSION WITH AGRNA AND GAPS WITH ANTISENSE TRANSCRIPTS AS A TARGET
|
WO2009090182A1
(en)
|
2008-01-14 |
2009-07-23 |
Santaris Pharma A/S |
C4'-substituted - dna nucleotide gapmer oligonucleotides
|
US8361980B2
(en)
|
2008-03-07 |
2013-01-29 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
WO2009124295A2
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
US20110263687A1
(en)
|
2008-04-07 |
2011-10-27 |
Riken |
Rna molecules and uses thereof
|
CA2635187A1
(en)
|
2008-06-05 |
2009-12-05 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Oligonucleotide duplexes and uses thereof
|
DK2310505T3
(da)
|
2008-06-30 |
2017-10-16 |
Roche Innovation Ct Copenhagen As |
Antidot-oligomerer
|
MY188457A
(en)
|
2008-10-03 |
2021-12-10 |
Opko Curna Llc |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
AU2009305639B2
(en)
|
2008-10-16 |
2016-06-23 |
Marina Biotech, Inc. |
Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
|
EP2405921A4
(en)
|
2009-01-26 |
2013-05-22 |
Protiva Biotherapeutics Inc |
COMPOSITIONS AND METHODS FOR INACTIVATION OF APOLIPOPROTEIN C-III EXPRESSION
|
KR101169373B1
(ko)
|
2009-02-04 |
2012-07-30 |
성균관대학교산학협력단 |
세포 내 전달능이 증가된 작은 간섭 rna 복합체
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
WO2010120969A1
(en)
|
2009-04-15 |
2010-10-21 |
Board Of Regents, The University Of Texas System |
Targeting of the mir-30 family and let-7 family as a treatment for heart disease
|
CA2768598A1
(en)
*
|
2009-07-22 |
2011-01-27 |
Cenix Bioscience Gmbh |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
US8431544B1
(en)
|
2009-08-27 |
2013-04-30 |
Idera Pharmaceuticals, Inc. |
Compositions for inhibiting gene expression and uses thereof
|
WO2011038031A1
(en)
*
|
2009-09-22 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting sirna agents
|
US9364495B2
(en)
|
2009-10-20 |
2016-06-14 |
Roche Innovation Center Copenhagen A/S |
Oral delivery of therapeutically effective LNA oligonucleotides
|
AU2010335039B2
(en)
*
|
2009-12-24 |
2015-03-26 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Molecule for treating an inflammatory disorder
|
WO2011117353A1
(en)
*
|
2010-03-24 |
2011-09-29 |
Mirrx Therapeutics A/S |
Bivalent antisense oligonucleotides
|
EP2558578B1
(en)
|
2010-04-13 |
2015-10-28 |
Life Technologies Corporation |
Compositions and methods for inhibition of nucleic acids function
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
EP2582397A4
(en)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR MODULATING THE INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
|
GB201010557D0
(en)
|
2010-06-23 |
2010-08-11 |
Mina Therapeutics Ltd |
RNA molecules and uses thereof
|
WO2012012443A2
(en)
|
2010-07-19 |
2012-01-26 |
Bennett C Frank |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
EP3702460A1
(en)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
EP2655621B1
(en)
|
2010-12-20 |
2018-05-23 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
US8557787B2
(en)
*
|
2011-05-13 |
2013-10-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
|
AU2012308320C1
(en)
|
2011-09-14 |
2018-08-23 |
Translate Bio Ma, Inc. |
Multimeric oligonucleotide compounds
|
WO2013080784A1
(ja)
|
2011-11-30 |
2013-06-06 |
シャープ株式会社 |
メモリ回路とその駆動方法、及び、これを用いた不揮発性記憶装置、並びに、液晶表示装置
|
US9404108B2
(en)
|
2012-03-04 |
2016-08-02 |
Bonac Corporation |
Micro-RMA inhibitor
|
WO2013173598A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating atp2a2 expression
|
EA201492119A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии apoa1 и abca1
|
AU2013262706A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating PTEN expression
|
WO2013173652A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
EP2850190B1
(en)
|
2012-05-16 |
2020-07-08 |
Translate Bio MA, Inc. |
Compositions and methods for modulating mecp2 expression
|
US9567581B2
(en)
|
2012-08-07 |
2017-02-14 |
The General Hospital Corporation |
Selective reactivation of genes on the inactive X chromosome
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
KR20150083920A
(ko)
|
2012-11-15 |
2015-07-20 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
항 apob 안티센스 접합체 화합물
|
US9580078B2
(en)
*
|
2014-09-25 |
2017-02-28 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Systems and methods for preheating hybrid vehicles
|
JP2017533721A
(ja)
|
2014-11-14 |
2017-11-16 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
タンパク質の調節のための化合物及び方法
|